Actinium Pharmaceuticals to Showcase at Roth Conference Actinium Pharmaceuticals is set to participate in the 37th Annual Roth Conference from March 16-18, 2025. The company will engage in one-on-one investor meetings on March 17 and 18, highlighting its advancements in targeted radiotherapies, including its flagship product Actimab-A, which is progressing through clinical trials for acute myeloid leukemia.1